KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating, Announces Target Price $191
Keybanc Maintains Overweight on ICU Medical, Lowers Price Target to $191
ICU Medical Analyst Ratings
Needham Maintains ICU Medical(ICUI.US) With Hold Rating
Needham Remains a Hold on ICU Medical (ICUI)
Raymond James Maintains ICU Medical(ICUI.US) With Buy Rating, Raises Target Price to $197
Raymond James Upgrades ICU Medical to Strong Buy From Outperform, Adjusts Price Target to $197 From $205
Analysts' Opinions Are Mixed on These Healthcare Stocks: ICU Medical (ICUI) and Zynex (ZYXI)
Needham Maintains ICU Medical(ICUI.US) With Hold Rating
KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating
ICU Medical Analyst Ratings
Jefferies Maintains ICU Medical(ICUI.US) With Buy Rating, Maintains Target Price $200
Jefferies Upgrades ICU Medical(ICUI.US) to Buy Rating, Raises Target Price to $200
KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating, Announces Target Price $209
ICU Medical Analyst Ratings
KeyBanc Maintains ICU Medical(ICUI.US) With Buy Rating
Needham Maintains ICU Medical(ICUI.US) With Hold Rating
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI) and Lexicon Pharmaceuticals (LXRX)
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Legend Biotech (LEGN) and ICU Medical (ICUI)
ICU Medical Is Maintained at Overweight by Keybanc